PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33402751-0	2021	Correction: IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.	Bleomycin	51-60	interleukin 4	Mus musculus	102-106	
33144678-0	2021	IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.	Bleomycin	39-48	interleukin 4	Mus musculus	90-94	
32272967-10	2020	Furthermore, the blockade of IL-4 signaling by IL-4Ralpha neutralizing antibodies attenuated the progression of fibrosis and the production of alpha2AP and HMGB1 in the bleomycin-induced mice.	Bleomycin	169-178	interleukin 4	Mus musculus	29-33	
29782549-7	2018	Bleomycin administration stimulated the mRNA expression of the profibrotic cytokines IL-13 and IL-4 and the M2 markers including arginase 1, Fizz1/Retnla, Ccl17 and Ccl24 in cells collected from broncho-alveolar lavage fluids (BALF), and S1pr2 deletion markedly diminished the stimulated expression of these genes.	Bleomycin	0-9	interleukin 4	Mus musculus	95-99	
12928422-3	2003	This led us to investigate whether the specific targeting of resident lung cells responsive to IL-4 and IL-13 exerted a therapeutic effect in an experimental model of IIP, namely the bleomycin-induced model of pulmonary fibrosis.	Bleomycin	183-192	interleukin 4	Mus musculus	95-99	
23258232-10	2013	Bleomycin-treated Pirb(-/-) mice displayed increased lung histopathology and an increased expression of collagen and of the IL-4-associated profibrogenic markers Relm-alpha, MMP-12, TIMP-1, and osteopontin, which were localized to alveolar macrophages.	Bleomycin	0-9	interleukin 4	Mus musculus	124-128	
18467694-4	2008	Bleomycin-treated wild-type mice exhibited dermal and lung fibrosis, hyper-gamma-globulinemia, autoantibody production, and enhanced serum and skin expression of various cytokines, including fibrogenic interleukin-4, interleukin-6, and transforming growth factor-beta1, all of which were inhibited by CD19 deficiency.	Bleomycin	0-9	interleukin 4	Mus musculus	202-215	
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 4	Mus musculus	33-37	
12928422-7	2003	Thus, this study demonstrates that IL-4- and/or IL-13-binding cells are required for the maintenance of pulmonary fibrosis induced by bleomycin and highlights the importance of further investigation of antifibrotic therapeutics that target these cells during pulmonary fibrosis.	Bleomycin	134-143	interleukin 4	Mus musculus	35-39	
12928422-4	2003	IL-4, IL-13, and their corresponding receptor subunits, IL-4Ralpha, IL-13Ralpha1, and IL-13Ralpha2, were maximally expressed at the mRNA and protein levels in whole lung samples on day 21 or 28 after an intratracheal bleomycin challenge.	Bleomycin	217-226	interleukin 4	Mus musculus	0-4	
12574379-3	2003	Lethal pulmonary injury after bleomycin treatment was higher in IL-4(-/-) vs IL-4(+/+) mice.	Bleomycin	30-39	interleukin 4	Mus musculus	64-68	
12574379-3	2003	Lethal pulmonary injury after bleomycin treatment was higher in IL-4(-/-) vs IL-4(+/+) mice.	Bleomycin	30-39	interleukin 4	Mus musculus	77-81	
12376365-0	2002	Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice.	Bleomycin	0-9	interleukin 4	Mus musculus	35-39	
12376365-5	2002	Comparing Bleo- to Sal-treated controls within each group of mice showed increases in all lung fibrosis parameters in IL-4 KO and WT, but not in any of the parameters in IL-4 TG mice.	Bleomycin	10-14	interleukin 4	Mus musculus	118-122	
12376365-6	2002	The severity of Bleo-induced fibrotic response was decreased in overexpressed IL-4 TG compared with IL-4 KO mice.	Bleomycin	16-20	interleukin 4	Mus musculus	78-82	
12376365-6	2002	The severity of Bleo-induced fibrotic response was decreased in overexpressed IL-4 TG compared with IL-4 KO mice.	Bleomycin	16-20	interleukin 4	Mus musculus	100-104	
9341282-8	1997	Expression of IL-4 was high in the bleomycin group, and was not inhibited in the glucocorticoid group.	Bleomycin	35-44	interleukin 4	Mus musculus	14-18	
11554783-0	2001	Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	56-65	interleukin 4	Mus musculus	5-18	
11554783-2	2001	To investigate the potential role of this cytokine, lung IL-4 expression was examined in a murine model of bleomycin-induced pulmonary fibrosis.	Bleomycin	107-116	interleukin 4	Mus musculus	57-61	
11554783-6	2001	Both in-situ hybridization and immunohistochemistry showed low or undetectable IL-4 expression in control lungs and in injured lungs before day 3 after bleomycin injection.	Bleomycin	152-161	interleukin 4	Mus musculus	79-83	
34719405-8	2021	When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group.	Bleomycin	78-87	interleukin 4	Mus musculus	124-128